Haemonetics Corporation (NYSE:HAE) Technical Strength Points To Near-Term Price Rebound

Haemonetics shows signs of technical stabilization after a pullback while underlying fundamentals and WMDST valuation indicate latent upside. The next several weeks should clarify whether momentum sustains a recovery toward longer-term averages.

Technical Analysis

ADX / DI+ / DI-: ADX registers at 46.46, indicating a very strong trend environment. DI+ sits at 12.79 and shows an increasing trend while DI- sits at 29.92 and shows a decreasing trend; that combination signals a shift toward bullish directional pressure even though DI- currently exceeds DI+.

MACD: MACD stands at -1.75 and has been increasing; the MACD line sits above the signal line (-2.23), a bullish crossing that suggests momentum has begun to turn positive despite MACD remaining negative in absolute terms.

MRO: MRO reads -23.13 with a dip & reversal. The negative value indicates price sits below the WMDST target and the dip & reversal pattern points to potential mean reversion toward that target.

RSI: RSI at 38.26 shows recent weakening but the indicator’s dip & reversal pattern signals easing downward momentum and the possibility of a near-term bounce as buying interest returns.

Price vs Moving Averages and Bands: The close at $50.98 sits above the 20-day average ($49.55) and 12-day EMA ($49.88) but below the 50-day ($55.08) and 200-day ($65.32) averages, implying short-term stabilization inside a longer-term downtrend. Price trades marginally above the Bollinger upper 1x standard-deviation band ($50.88), suggesting short-term strength but still below the cloud (Senkou A $58.71 / Senkou B $65.31), which denotes multi-week resistance overhead. The super trend upper at $51.45 aligns with the 26-day EMA, marking a near-term resistance reference for momentum confirmation.

 


Fundamental Analysis

Profitability & Margins: EBIT totals $53,872,000 and EBITDA totals $82,630,000. Operating (EBIT) margin equals 16.76%. That margin sits below the industry peer mean of 18.47% and close to the industry peer median of 17.48%. EBIT margin contracted QoQ by 22.32% but expanded YoY by 41.74%, showing notable year-over-year improvement offset by a recent quarterly compression.

Revenue & Growth: Total revenue registers $321,394,000. YoY revenue growth measures 34.30%, while sequential revenue fell QoQ by 45.92%. The mix of strong annual growth and a large quarter-to-quarter decline suggests timing and portfolio changes affected the most recent period.

Earnings & Cash Flow: Reported EPS equaled $1.10 versus an estimate of $1.02, producing an EPS surprise of 7.84%. Operating cash flow reached $17,395,000 with free cash flow at $13,641,000 and a free cash flow yield of 0.44%. Free cash flow declined significantly QoQ and YoY, consistent with the reported negative free cash flow growth rates.

Balance Sheet & Leverage: Cash and short-term investments total $292,898,000 while net debt stands at $931,884,000. Debt to EBITDA measures 14.82x and debt to equity equals 1.39, reflecting elevated leverage. Interest coverage registers 6.19x, indicating the company covers interest expense but operates with meaningful indebtedness.

Returns & Efficiency: Return on equity equals 3.86% and return on assets equals 1.39%; both show QoQ declines and modest absolute returns. Asset turnover sits at 0.131, near the industry peer mean of 0.121, indicating revenue generation per asset sits around peer average.

Valuation Metrics: Trailing P/E equals 65.75 and forward P/E equals 51.23; price-to-book stands at 3.52. Forward PEG and PEG metrics show negative values, reflecting a growth-rate dynamic that produces unconventional PEG readings. WMDST values the stock as under-valued, a valuation view that must be weighed against the company’s elevated leverage and near-term cash-flow compression.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-07
NEXT REPORT DATE: 2025-11-05
CASH FLOW  Begin Period Cash Flow 306.8 M
 Operating Cash Flow 17.4 M
 Capital Expenditures -3.75 M
 Change In Working Capital -55.48 M
 Dividends Paid
 Cash Flow Delta -13.87 M
 End Period Cash Flow 292.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 321.4 M
 Forward Revenue 151.8 M
COSTS
 Cost Of Revenue 129.2 M
 Depreciation 17.4 M
 Depreciation and Amortization 28.8 M
 Research and Development 16.3 M
 Total Operating Expenses 267.5 M
PROFITABILITY
 Gross Profit 192.2 M
 EBITDA 82.6 M
 EBIT 53.9 M
 Operating Income 53.9 M
 Interest Income
 Interest Expense 8.7 M
 Net Interest Income -8.70 M
 Income Before Tax 45.2 M
 Tax Provision 11.1 M
 Tax Rate 24.7 %
 Net Income 34.0 M
 Net Income From Continuing Operations 34.0 M
EARNINGS
 EPS Estimate 1.02
 EPS Actual 1.10
 EPS Difference 0.08
 EPS Surprise 7.843 %
 Forward EPS 1.33
 
BALANCE SHEET ASSETS
 Total Assets 2.5 B
 Intangible Assets 1.1 B
 Net Tangible Assets -175.63 M
 Total Current Assets 913.2 M
 Cash and Short-Term Investments 292.9 M
 Cash 292.9 M
 Net Receivables 200.8 M
 Inventory 360.5 M
 Long-Term Investments 196.3 M
LIABILITIES
 Accounts Payable 46.0 M
 Short-Term Debt 303.9 M
 Total Current Liabilities 531.4 M
 Net Debt 931.9 M
 Total Debt 1.2 B
 Total Liabilities 1.6 B
EQUITY
 Total Equity 882.3 M
 Retained Earnings 356.0 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 18.30
 Shares Outstanding 48.159 M
 Revenue Per-Share 6.67
VALUATION
 Market Capitalization 3.1 B
 Enterprise Value 4.0 B
 Enterprise Multiple 48.875
Enterprise Multiple QoQ 20.985 %
Enterprise Multiple YoY -18.639 %
Enterprise Multiple IPRWA high: 123.29
median: 110.415
mean: 94.203
HAE: 48.875
low: -147.649
 EV/R 12.566
CAPITAL STRUCTURE
 Asset To Equity 2.791
 Asset To Liability 1.558
 Debt To Capital 0.581
 Debt To Assets 0.497
Debt To Assets QoQ -0.452 %
Debt To Assets YoY 24649.254 %
Debt To Assets IPRWA high: 0.843
HAE: 0.497
mean: 0.298
median: 0.289
low: 0.0
 Debt To Equity 1.388
Debt To Equity QoQ -6.967 %
Debt To Equity YoY 24512.943 %
Debt To Equity IPRWA high: 3.369
HAE: 1.388
mean: 0.627
median: 0.579
low: -0.395
PRICE-BASED VALUATION
 Price To Book (P/B) 3.521
Price To Book QoQ -6.865 %
Price To Book YoY -28.807 %
Price To Book IPRWA high: 16.759
median: 6.869
mean: 6.297
HAE: 3.521
low: -5.981
 Price To Earnings (P/E) 65.753
Price To Earnings QoQ 26.683 %
Price To Earnings YoY -23.383 %
Price To Earnings IPRWA high: 249.6
mean: 136.779
median: 121.658
HAE: 65.753
low: -167.592
 PE/G Ratio -5.824
 Price To Sales (P/S) 9.666
Price To Sales QoQ 2.977 %
Price To Sales YoY -27.431 %
Price To Sales IPRWA high: 73.117
mean: 32.511
median: 24.499
HAE: 9.666
low: 0.6
FORWARD MULTIPLES
Forward P/E 51.229
Forward PE/G -4.538
Forward P/S 20.442
EFFICIENCY OPERATIONAL
 Operating Leverage 8.792
ASSET & SALES
 Asset Turnover Ratio 0.131
Asset Turnover Ratio QoQ -1.417 %
Asset Turnover Ratio YoY -7.834 %
Asset Turnover Ratio IPRWA high: 0.412
HAE: 0.131
median: 0.124
mean: 0.121
low: 0.008
 Receivables Turnover 1.593
Receivables Turnover Ratio QoQ -0.086 %
Receivables Turnover Ratio YoY -3.297 %
Receivables Turnover Ratio IPRWA high: 3.133
mean: 1.735
median: 1.672
HAE: 1.593
low: 0.374
 Inventory Turnover 0.356
Inventory Turnover Ratio QoQ -6.223 %
Inventory Turnover Ratio YoY -23.734 %
Inventory Turnover Ratio IPRWA high: 2.014
mean: 0.649
median: 0.568
HAE: 0.356
low: 0.084
 Days Sales Outstanding (DSO) 57.268
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 260.487
Cash Conversion Cycle Days QoQ 12.136 %
Cash Conversion Cycle Days YoY 28.469 %
Cash Conversion Cycle Days IPRWA high: 448.876
HAE: 260.487
mean: 170.635
median: 167.784
low: -175.55
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.842
 CapEx To Revenue -0.012
 CapEx To Depreciation -0.216
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.8 B
 Net Invested Capital 2.1 B
 Invested Capital 2.1 B
 Net Tangible Assets -175.63 M
 Net Working Capital 381.8 M
LIQUIDITY
 Cash Ratio 0.551
 Current Ratio 1.718
Current Ratio QoQ 6.251 %
Current Ratio YoY -54.331 %
Current Ratio IPRWA high: 19.146
mean: 2.552
HAE: 1.718
median: 1.686
low: 0.027
 Quick Ratio 1.04
Quick Ratio QoQ 5.505 %
Quick Ratio YoY -55.28 %
Quick Ratio IPRWA high: 12.697
mean: 1.883
median: 1.167
HAE: 1.04
low: 0.315
COVERAGE & LEVERAGE
 Debt To EBITDA 14.822
 Cost Of Debt 0.535 %
 Interest Coverage Ratio 6.19
Interest Coverage Ratio QoQ -94.811 %
Interest Coverage Ratio YoY 8.321 %
Interest Coverage Ratio IPRWA high: 52.298
mean: 15.492
median: 11.456
HAE: 6.19
low: -88.481
 Operating Cash Flow Ratio 0.091
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 37.485
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 0.455 %
 Revenue Growth -2.784 %
Revenue Growth QoQ -45.921 %
Revenue Growth YoY 34.298 %
Revenue Growth IPRWA high: 26.158 %
median: 8.281 %
mean: 6.347 %
HAE: -2.784 %
low: -39.052 %
 Earnings Growth -11.29 %
Earnings Growth QoQ -368.682 %
Earnings Growth YoY -184.677 %
Earnings Growth IPRWA high: 166.667 %
mean: 11.407 %
median: 9.851 %
HAE: -11.29 %
low: -180.612 %
MARGINS
 Gross Margin 59.816 %
Gross Margin QoQ 2.435 %
Gross Margin YoY 14.956 %
Gross Margin IPRWA high: 91.006 %
median: 63.683 %
mean: 62.194 %
HAE: 59.816 %
low: -7.085 %
 EBIT Margin 16.762 %
EBIT Margin QoQ -22.319 %
EBIT Margin YoY 41.739 %
EBIT Margin IPRWA high: 33.709 %
mean: 18.468 %
median: 17.478 %
HAE: 16.762 %
low: -200.872 %
 Return On Sales (ROS) 16.762 %
Return On Sales QoQ -22.319 %
Return On Sales YoY 41.739 %
Return On Sales IPRWA high: 39.857 %
mean: 18.874 %
median: 18.374 %
HAE: 16.762 %
low: -215.416 %
CASH FLOW
 Free Cash Flow (FCF) 13.6 M
 Free Cash Flow Yield 0.439 %
Free Cash Flow Yield QoQ -86.501 %
Free Cash Flow Yield YoY -159.405 %
Free Cash Flow Yield IPRWA high: 4.685 %
median: 0.712 %
mean: 0.677 %
HAE: 0.439 %
low: -19.501 %
 Free Cash Growth -86.483 %
Free Cash Growth QoQ -146.365 %
Free Cash Growth YoY -46.22 %
Free Cash Growth IPRWA high: 310.383 %
mean: 86.228 %
median: 14.619 %
HAE: -86.483 %
low: -376.098 %
 Free Cash To Net Income 0.401
 Cash Flow Margin 15.034 %
 Cash Flow To Earnings 1.42
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.385 %
Return On Assets QoQ -40.507 %
Return On Assets YoY -14.506 %
Return On Assets IPRWA high: 16.404 %
mean: 1.742 %
median: 1.686 %
HAE: 1.385 %
low: -35.697 %
 Return On Capital Employed (ROCE) 2.79 %
 Return On Equity (ROE) 0.039
Return On Equity QoQ -45.399 %
Return On Equity YoY -8.99 %
Return On Equity IPRWA high: 0.175
HAE: 0.039
median: 0.032
mean: 0.028
low: -0.524
 DuPont ROE 3.996 %
 Return On Invested Capital (ROIC) 1.926 %
Return On Invested Capital QoQ -32.61 %
Return On Invested Capital YoY -120.023 %
Return On Invested Capital IPRWA high: 5.672 %
median: 2.571 %
mean: 2.223 %
HAE: 1.926 %
low: -19.888 %

Six-Week Outlook

Technical indicators collectively favor stabilization and a probative rebound over the next six weeks. A bullish MACD crossover and increasing DI+ alongside RSI and MRO dip-and-reversal patterns support a short-term recovery attempt from current levels. Price remains below major moving averages and the Ichimoku cloud, so momentum must sustain to retake the 50-day average and reduce the dominance of longer-term resistance.

Fundamentals present a mixed backdrop: strong YoY revenue growth and year-over-year margin expansion contrast with QoQ compression, shrinking free cash flow, and elevated leverage. The WMDST under-valued determination aligns with the technical setup for a mean-reversion move, but leverage and recent cash-flow trends pose conditions for volatility. Monitor whether momentum indicators continue to improve; persistence of bullish signals would increase the probability of a sustained multi-week rebound, while reassertion of DI- or a falling ADX would suggest renewed directional weakness.

About Haemonetics Corporation

Haemonetics Corporation (NYSE:HAE) develops advanced blood management solutions, offering a wide range of products and services that improve the safety and efficiency of blood and plasma collection, processing, and transfusion. Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics designs automated plasma collection systems like NexSys PCS and PCS2, which enhance plasmapheresis processes. The company’s integrated software solutions, such as NexLynk DMS and Donor360, streamline donor management and operational workflows in plasma centers. In blood collection, Haemonetics provides both automated and manual systems, including MCS apheresis equipment and the SafeTrace Tx blood bank information system, ensuring accurate collection and storage of blood components. For hospital-based applications, Haemonetics offers the TEG and HAS hemostasis analyzers, which provide crucial insights into patient hemostasis, assisting clinicians in making informed treatment decisions. The Cell Saver Elite+ system supports autologous blood recovery during surgeries, while the VASCADE platform aids in vascular closure procedures. Haemonetics maintains a robust distribution network, empowering healthcare providers globally and fostering advancements in patient care and operational efficiency.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.